News und Analysen

Biogen's fourth quarter 2024 performance presents a complex picture for investors, with revenue climbing 2.9% to $2.46 billion and adjusted earnings per share reaching $3.44, surpassing market

Gilead Sciences witnessed a remarkable surge in its stock performance on Wednesday, with shares climbing over 8% to reach a new 52-week high of $104.64. The biotechnology company's impressive

Waters Corporation exceeded expectations in the fourth quarter of 2024, demonstrating robust financial performance across key metrics. The analytical instrument and laboratory technology specialist

Pfizer and Astellas Pharma have achieved a significant breakthrough in advanced bladder cancer treatment, demonstrating remarkable success with their combination therapy of PADCEV and KEYTRUDA. The

Die Edwards Lifesciences Corporation steht heute im Fokus der Anleger, da der US-amerikanische Medizintechnikkonzern nach Börsenschluss seine Geschäftsergebnisse für das vierte Quartal 2024

Die Tochtergesellschaft UMR der UnitedHealth Group hat sich zu einer bedeutenden Zahlung von mindestens 20,3 Millionen Dollar bereit erklärt, um eine Auseinandersetzung mit dem US-Arbeitsministerium

Die Vertex Pharmaceuticals verzeichnet aktuell eine rückläufige Kursentwicklung an den Börsen. Der Biotech-Konzern, der sich auf die Entwicklung von Medikamenten für schwere Erkrankungen

Pfizer's recent quarterly performance demonstrates a significant turnaround, with revenues surging nearly 25% to reach $17.76 billion. The pharmaceutical giant has shown remarkable improvement in

Pfizer's stock experienced a modest decline of 0.8% to $26.24 in Thursday's New York trading session, yet the pharmaceutical giant's underlying performance tells a more compelling story. The company

Iqvia demonstrated robust performance in the fourth quarter of 2024, with revenue climbing 2.3% year-over-year to reach $3.96 billion. The company's Technology & Analytics Solutions segment emerged

Regeneron Pharmaceuticals has exceeded market expectations with its fourth-quarter performance, posting an adjusted earnings per share of $12.07, significantly surpassing analyst projections of

Pharmaceutical giant Pfizer is embarking on a significant strategic shift with a heightened focus on artificial intelligence through a multi-year collaboration with technology firm Data4Cure. This

UnitedHealth Group faced market turbulence on Tuesday as its shares dropped approximately 1.5% following serious allegations from a prominent hedge fund manager. The investor raised concerns about

Die Stryker Aktie demonstriert zu Beginn des Jahres 2025 eine bemerkenswerte Marktdynamik. Der aktuelle Kurs liegt bei 392,36 USD und verzeichnet einen Anstieg von 0,34% gegenüber dem Vortag. Mit

Die Edwards Lifesciences Aktie verzeichnet aktuell eine moderate Abwärtsbewegung an der Börse. Der Aktienkurs des US-amerikanischen Medizintechnikunternehmens liegt derzeit bei 71,35 USD und weist

Amgen's fourth-quarter performance in 2024 presented a mixed picture, with profits declining despite robust revenue growth. The biotech giant reported a 18% decrease in quarterly profit to $627

Pfizer's recent breakthrough in cancer research is painting a promising picture for the pharmaceutical giant, despite its stock experiencing a slight dip of 0.9% to $26.27. The company has achieved

Idexx Laboratories, a leading provider of animal healthcare solutions, has demonstrated exceptional performance in the fourth quarter, substantially exceeding market expectations. The company

Die Illumina-Aktie zeigt sich kurz vor der Veröffentlichung der Q4-Geschäftszahlen 2024 leicht rückläufig. Am vergangenen Handelstag verzeichnete das Genforschungsunternehmen einen Kursrückgang von